background
Recently, a research team led by Professor Dahong Zhang and Professor Qi Zhang from the Department of Urology, Institute of Urology, and Translational Medicine Center of Zhejiang Provincial People’s Hospital discovered that polyarginine peptide R11, which targets bladder tumors, can directly bind to actin, destabilize G-actin tetramers, and cause cascade disassembly of G-actin tetramers. actin-plectin-vimentin/ITGβ4 axis (referred to as the “cytoskeletal domino effect”). This significantly impairs the migratory ability of bladder cancer (BCa) cells and persistently suppresses metastasis (Figure 1). This study further revealed that presenting R11 in the form of nanoscale multivalent aggregates amplified its actin-disrupting and anti-metastatic effects. This strategy is naturally compatible with local delivery routes such as bladder instillation and aerosol inhalation and shows clear clinical application potential.
Research progress
The team of Professors Dahong Zhang and Qi Zhang proposed and validated the use of polyarginine peptide R11 to target bladder tumors as a new strategy to “precisely control actin”. They found that the domino effect induced by R11 could effectively suppress BCa metastasis. Key highlights of the study include:
1. R11 selectively enters tumor cells, directly interacts with actin, and disrupts the stability of G-actin tetramers.
Through molecular dynamics simulations and microscale thermophoretic analysis, we found that highly positively charged R11 forms hydrogen bonds and salt bridges with negatively charged actin and is embedded in the gap of G-actin tetramers. This interaction blocks normal G-actin interactions and polymerization, disrupting the formation and maintenance of the F-actin network. A significant decrease in the intracellular F/G-actin ratio suggests a severe imbalance in actin dynamics.
2. R11 causes a “cytoskeletal domino effect” – actin → plectin → vimentin / ITGβ4 cascade breakdown:
Plectin is a hub protein that links actin with intermediate filaments (vimentin) and integrins (ITGβ4). When R11 disrupts actin-plectin binding, the interaction between plectin and vimentin/ITGβ4 is weakened or abolished, leading to loss of global cytoskeletal polarity and mechanical connectivity. This greatly reduces the possibility of cell migration and metastasis. The authors aptly refer to this process as the “cytoskeletal domino effect.”
3. Multivalent aggregates of nanoparticles significantly amplify anti-metastatic potential (engineered amplification strategy):
The authors immobilized R11 on PEG-modified gold nanoparticles (Au-PEG-R11) and compared nanoparticles of different sizes/covering densities. The results showed that multivalency and high density loading (e.g., 50 nm Au-PEG-R11) significantly enhanced the interference with actin and inhibition of metastasis. This indicates that by using nanoparticle engineering strategies (such as multivalency and dense packing), molecular-scale interactions can be amplified and translated into cellular-level structural and functional changes, thereby improving therapeutic efficacy.
Future outlook
R11 is not only an ideal functional ligand for surface functionalization of bladder instillation nanodrugs, but also a “self-therapeutic” molecule. This study proposes and validates a complete anti-metastasis strategy from mechanism to engineering. R11 directly interferes with actin, causing cytoskeletal disruption and preventing tumor cell migration and colonization at distant sites. Nanoscale multivalent assemblies further amplify this effect and exhibit excellent engineering plasticity and drug potential. Based on these findings, future clinical translation directions may focus on the following aspects:
1. Prioritize localized delivery:
R11 originally has the ability to take up bladder tumors. Bladder instillation and aerosol inhalation (for BCa lung metastases) have become the preferred clinical administration routes as they can achieve high local concentrations while minimizing systemic exposure and toxicity.
2. Optimization of nanoparticle formulation to increase efficacy and persistence:
Multivalent nanoparticle platforms such as Au-PEG-R11 have shown amplifying effects. Further formulation optimization (e.g., biodegradable carriers, PEG density control, controlled release) may improve tumor targeting and safety.
3. Combination therapy strategy:
R11 primarily targets migration/invasion machinery and alters cell adhesion/ECM dynamics and tumor microenvironment. In combination with chemotherapy, radiotherapy, or immune checkpoint inhibitors, it may be possible to synergistically suppress both the primary tumor and metastases.
4. Immunocompatibility and long-term safety evaluation are essential.
Although local delivery and nanoparticle encapsulation reduce systemic toxicity, the effects of R11 and its carriers on immune activation, immune tolerance, and long-term tissue toxicity need to be systematically evaluated to ensure a safe clinical route.
sauce:
Science and Technology Review Publishing
Reference magazines:
Liu, Z. Others. (2026). Interaction between polyarginine peptide R11 and actin induces a domino effect on cytoskeletal remodeling and inhibits bladder cancer metastasis. the study. DOI: 10.34133/research.1109. https://spj.science.org/doi/10.34133/research.1109
